HScore

Scores above 169 have greater than 90% accuracy

The HScore estimates the probability of secondary HLH using weighted clinical, laboratory, and bone‑marrow parameters.

Immunosuppression?
No0Yes+18
Patient Temp?
less than 101.1F (38.4C)0101.1 - 102.9F (38.4 - 39.4C)+33greater than 102.9F (39.4C)+49
Organomegaly
No0Hepatomegaly OR splenomegaly+23Hepatomegaly AND splenomegaly+38
Cytopenia?
1 Lineage only02 Lineages+24All 3 Lineages+34
Ferritin Level?
less than 2000 ng/mL02000 - 6000 ng/mL+35more than 6000 ng/mL+50
Triglyceride Level?
less than 132.7 mg/dL (1.5 mmol/L)0132.7 - 354 mg/dL (1.5 - 4 mmol/L)+44more than 354 mg/dL (4 mmol/L)+64
Fibrinogen Level?
more than 250 mg/dL (2.5 g/L)0250 mg/dL (2.5 g/L) or less+30
AST Level?
less than 30 U/L030 U/L or greater+35
Bone Marrow Aspirate Hemophagocytic?
No0Yes+35

Indications for Use

Used when evaluating suspected secondary HLH/MAS in adults with unexplained hyperinflammation (fever, cytopenias, organomegaly, hyperferritinemia). Provides probability of HLH using weighted clinical/lab variables and supports early diagnostic decision‑making. Validated cut‑off ≥169 gives ~82–95% sensitivity and 66–88% specificity across multicenter cohorts 1 [Level I evidence]. Highest utility early in illness to distinguish HLH from sepsis‑like syndromes 2 [Level II evidence].

Insights & Cautions

Start by noting it performs best as a screening tool but is not definitive: an HScore ≥169 is highly sensitive (~82–96%) yet poorly specific (~17–88%) for adult HLH, with c‑statistics ~0.74–0.76 in validations 1 [Level II evidence]; 2 [Level II evidence]. Use cautiously in malignancy-associated HLH, where inflammatory markers may reflect tumor biology. Low scores do not exclude HLH—clinical judgment and HLH‑2004 criteria remain essential.